What We're Reading: Page 256
Industry reads hand-picked by our editors
Aug 10, 2018
-
Kaiser Health News
Trump administration sinks teeth into paring down drug prices, on 5 key points
-
Bloomberg
Red flags raised at Chinese heart drug maker year before recall
-
BioCentury
FDA rolls out guidance for seamless cancer trials
-
The Washington Post
Death reports make the opioid crisis personal for doctors
Aug 09, 2018
-
The Wall Street Journal
New Marijuana-Based Epilepsy Treatment to Cost $32,500 a Year
-
Bloomberg
The $250 Biohack That's Revolutionizing Life With Diabetes
-
MIT Technology Review
US scientist who edited human embryos with CRISPR responds to critics
Aug 08, 2018
-
Xconomy
With big Takeda deal at launch, can Ambys keep control of its future?
-
Bloomberg Opinion
Carl Icahn knows it's never too late to derail a deal
-
Boston Business Journal
As FDA decision looms, Alnylam triples Kendall footprint, plans to double staff
Aug 07, 2018
-
Los Angeles Times
Sorry about your Stage 3 cancer. Here's a bill for $21,000 in charges you thought were covered
-
CNN
At 18, she launched a biotech startup. Four years later, she's blazing a trail in the VC world
-
Reuters
Biotech entrepreneur Drayson plans to list new AI drug research firm
-
The Washington Post
She made a career out of studying the brain. Then hers veered off course.
Aug 06, 2018
-
The Wall Street Journal
How China is evolving from a maker of copycat medicines into a producer of complex drugs
-
NPR
How one family's fight with epilepsy led to the first marijuana-based pharmaceutical
-
Associated Press
Feds probe firm's ties to illegal pharma merchants
-
TechCrunch
Boston-area startups are on pace to overtake NYC venture totals
Aug 03, 2018
Aug 02, 2018
-
The New York Times
Trump finally picks a science adviser. And scientists? They seem relieved.
-
STAT
Did a blockbuster drug make hundreds gamble compulsively? A legal fight may decide what science can't confirm
-
Bloomberg
Facing wave of opioid lawsuits, drug companies sprinkle charity on hard-hit areas
-
The Washington Post
Childhood cancer survivors face ‘financial toxicity’
Previous
